Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ123MR)

This product GTTS-WQ123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ123MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7051MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ11639MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ7167MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ3633MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ14523MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ7111MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ15078MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ3857MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW